

Mean Vitamin D levels in 19 European Countries & COVID-19 Mortality over 10 months

Authors: Amar Ahmad ¹, Christian Heumann ², Raghiv Ali ³, Tim Oliver ⁴

¹ Research Scientist, New York University, Abu Dhabi, email asa12@nyu.edu

ORCID 0000-0002-1245-868X

² Depart Statistics, Ludwig-Maximilians-Universität München,

email christian.heumann@stat.uni-muenchen.de

³ Public Health Research Center, New York University Abu Dhabi email ra107@nyu.edu

ORCID 0000-0002-8225-4674

⁴ Professor Emeritus Barts Cancer Institute, London, email r.t.oliver@qmul.ac.uk

ORCID 000-0002-7879-8943

Key words: Population, Vitamin D, Europe, COVID-19, Mortality, Poisson mixed effect model

Strengths of this study

Large number of different European populations studied with different policies of food fortification and different population Vitamin D levels

Ten months of longitudinal study during rise and fall and rise again of the epidemic

Limitations of this study

Based on population Vitamin D levels published before the beginning of the pandemic. Though there hasn't been a pan-European national/international health education initiative about Vitamin D and COVID-19 infection, it has been well covered in the media and could have resulted in changes, though probably minor, at the national level. Because there have been many differences in response to the pandemic in these countries, there could be other factors involved as well

Corresponding author:

Tim Oliver, Barts Cancer Institute, London, UK. EC1M 6BQ

Email: r.t.oliver@qmul.ac.uk

Phone: +44 7768 876805

Abstract word count 250

Text word count 2210

ABSTRACT

Objectives: Reports early in the epidemic linking low mean national Vitamin D level with increased COVID-19 death, and until recently little research on the impact of Vitamin D deficiency on severity of COVID-19, led to this update of the initial report studying mortality up to the end of January 2021.

Methods, Design and Setting: Coronavirus pandemic data for 19 European countries were downloaded from Our World in Data, which was last updated on January 24, 2021. Data from March 21, 2020 to January 22, 2021 were included in the statistical analysis. Vitamin-D (25)-HD mean data were collected by literature review. Poisson mixed-effect model was used to model the data.

Results: European countries with Vitamin-D (25)-HD mean less than or equal to 50 have higher COVID-19 death rates as compared with European countries with Vitamin-D (25)-HD mean greater than 50, relative risk of 2.155 (95% CI: 1.068 – 4.347, p-value = 0.032). A statistically significant negative moderate Spearman rank correlation was observed between Vitamin-D (25)-HD mean and the number of COVID-19 deaths for each 14-day period during the COVID-19 pandemic time period.

Conclusions: The observation of the significantly lower COVID-19 mortality rates in countries with lowest annual sun exposure but highest mean Vitamin-D (25)-HD levels provides support for more awareness and possible use of food fortification. The need to consider re-configuring vaccine strategy due to emergence of large number of COVID-19 variants and studies identifying poor responders to Vaccine provides an opportunity to undertake therapeutic randomized control trials to confirm these observations.

INTRODUCTION

The COVID-19 pandemic has created a major global health problem because of its high number of patients requiring intensive care and death rate particularly in patients over 65-70 yrs of age. (1-3) The impact has been unequal globally, primarily due to the younger populations in, for example, Africa where the majority of the population are under 65 (4) not getting ill, except for South Africa (5) . Non-pharmaceutical interventions used to control transmission, particularly universal lockdowns, have been the primary means of reducing case incidence and this has caused serious economic harm in many countries (6-8).

Vitamin-D has a potential role in infections, which is implied from its effect on the innate and adaptive immune responses (9) and the fact that respiratory infections tend to disappear during summer. Furthermore, there is existing evidence for an association between vitamin-D deficiency and a risk of influenza infection and when the individuals have Vitamin D deficiency, they have reduced respiratory infection when entered into supplementation randomized trials (10, 11), though dose and scheduling is far from clear.

In the 12 months since the onset of the COVID-19 pandemic, no major trials of Vitamin D have been completed. There has however been increasing interest with 5 reports demonstrating a strong impact of Vitamin D deficiency on the behavior of COVID-19 illness (12-16) and limited data from three small randomized trial reporting improved clinical outcome in patients receiving replacement therapy (17). This has been followed by posting on-line of a 930 cluster randomized trial with Calcifediol reporting a 64% reduction in deaths which has generated considerable criticism for methodology and is currently being further revision (18) .

Population-based mean levels of vitamin-D were shown in an analysis during the first 2 months of the pandemic to correlate inversely with COVID-19 mortality (19). The aim of this paper is to update these analyses after 11 months of the pandemic through statistical analysis focusing on the association between vitamin D (25)-HD average and COVID-19 mortality rates based on public record of the number of COVID-19 deaths in 2 week periods from 21/02/2020 – 22/01/2021 in 19 European countries.

METHODS

STUDY DESIGN

Coronavirus pandemic data for 19 European countries were downloaded from “Our World in Data” (see <https://ourworldindata.org/coronavirus>), which was last updated on January 24, 2021 (20). Data from March 21, 2020 to January 22, 2021 were included in the statistical analysis. Data on vitamin D deficiency were collected via a literature review (19, 21, 22).

STATISTICAL ANALYSIS

Last observation carried forward was used to impute missing values, whenever data were not available (23). The vitamin D mean value (19) was missing for Greece which was (single) imputed by the median vitamin D value of all countries.

The crude mortality rate (CMR) was computed using data from January 22, 2021 by dividing the total number of COVID-19 deaths by the corresponding population per 100,000. Spearman rank correlation was estimated between vitamin D averages variable and the number of COVID-19 total deaths and the crude mortality rate respectively. A jackknife empirical 95% confidence interval for Spearman's correlation was computed (24).

Then the vitamin D values were binarised into 0 (vitamin D \leq 50) versus 1 (vitamin D $>$ 50). Wilcoxon rank-sum test was used to compare the total number of COVID-19 deaths and CMR between countries who have vitamin D averages of less than or equals to 50 versus countries that have vitamin D averages greater than 50 respectively.

Univariate and bivariate generalised linear regression models with Quasi-Poisson distribution were performed using the total number of COVID-19 deaths by January 22nd 2021 as an outcome. The predictors were the categorical vitamin D variable and the proportion of age 70+ for each country. The population variable was added as an offset in the model. Relative risks (RRs) and 95% confidence intervals (95% CI) were computed with corresponding z- and p-values.

A time-point variable of 22 time-periods of 14 days was created between 01/03/2020 and 22/01/2021 at each time-point. A Spearman rank correlation was used to evaluate the association between the

number of COVID-19 deaths at each time-point and the average of vitamin D of the 19 European countries. To compute an approximate 95% confidence interval (using the normality approximation) for the estimated Spearman rank correlation, a leave-one-time-period-out cross-validation was performed at each time-point.

A Poisson mixed effects regression model (25) was fitted with the total number of new COVID-19 deaths as an outcome. The percentage of age 70+ and binarized vitamin D were used as fixed effect predictors. The time-periods and the 19 European countries variable were used as random effect variables with (04/04/2020 to 17/04/2020) and the UK as reference groups respectively. The populations variable was added as an offset in the model. Relative risks (RRs) and 95% confidence intervals (95% CI) were computed with corresponding z- and p-values.

All applied statistical tests were two-sided, p-value < 0.05 were considered statistically significant. Statistical analyses were performed in R version 4.0.2 (26)(25)(25)(25).

RESULTS

The data used in this statistical analysis are shown in Table 1 in descending order of the countries level of Vitamin D level. It can be seen visually that the crude mortality rate (CMR) increases with decreasing mean Vitamin D level. A statistically significant moderate negative Spearman's ρ correlation was observed between the total number of COVID-19 deaths and the average of vitamin D, $\rho = -0.516$ (95% CI: -0.860 – -0.168) as well as between COVID-19 crude mortality rates and the average of vitamin D, $\rho = -0.430$ (95% CI: -0.805 – -0.081) (Figure 1). A similar result was seen in the numbers of Table 2. This shows the Spearman's rho correlation analysis between the number of new COVID-19 deaths at each of the 22 time periods and the same reported mean vitamin D used on each occasion. All the observed negative Spearman's rho correlation values were statistically significant.

Figure 1 shows the distribution of the total number of COVID-19 deaths and CMR within the vitamin D group (≤ 50 versus > 50) respectively. A statistically significant difference was observed between the vitamin D groups (≤ 50 versus > 50), Wilcoxon sum-rank test p-value of 0.036 and 0.012 respectively.

Table 3 shows the results of the univariate and bivariate generalised linear regression model with family quasi-Poisson using the total number of COVID-19 deaths from 22/03/2020 as an outcome. The countries with vitamin D average ≤ 50 have higher COVID-19 death rates as compared with countries

with vitamin D average > 50, RR of 1.642 (95% CI 1.274 – 2.118, p-value = 0.02) univariately. This result holds after adjusting for the population age structure (ie percentage of the population with age 70+), RR of 1.663 (95% CI: 1.293 – 2.140, p-value < 0.0001). This result is similar to the result from the fitted Poisson mixed-effects models (Table 4), where countries with vitamin D average \leq 50 have higher COVID-19 death rates as compared with countries with vitamin D average > 50 before and after adjusting for population age structure with RR of 2.197 (95% CI: 1.131 – 4.271, p-value = 0.02) and 2.155 (95% CI: 1.068 – 4.347, p-value = 0.032) respectively. The percentage of age 70+ was not statistically significant in either a univariate and bivariate regression models (Table 3 and 4).

Discussion

It is now nearly 20 years since the emergence of rickets in UK immigrant families led to introducing supplements for pregnant women. Since this time there has been continuous conclusion, in part due to confounding variables such as the health benefits of exercise increasing Vitamin D levels, that Vitamin D was only important for bone and muscle health. Despite regularly assuring the UK population that the pandemic would lessen during our summer months, there has been no funding for clinical trials of Vitamin D supplements and negative reviews mainly based on others data by PHE, SACN, NICE (<https://www.nice.org.uk/guidance/ng187>). This negative view focuses attention onto an on-going controversy dating back to the 1950s, i.e. whether food should be supplemented with Vitamin D. In the early years after the 2nd world war in the UK enthusiasm for supplementation was so great that children died from overdose hypercalcaemia. As a result, the UK has been more reluctant to sanction such supplementation while it has been used increasingly used in the Scandinavian countries (27). This could explain why most of these countries, despite having less sunshine than the UK, have lower RRs. The one exception is Sweden which had a policy of attempting to generate hard immunity. The increasing data to support this interpretation started with Meltzer et al studying Vitamin D levels in 489 attendees in an urban medical centre in Chicago (13). They demonstrated a higher frequency of acquisition of COVID-19 cases in the Vitamin D deficient group (21.9%) than in the sufficient group (12.2%). This was subsequently confirmed by a much larger study (14) and two smaller studies (12, 15). The Boston group also reported data suggesting a link between Vitamin D deficiency and increased severity of disease (16). In a recent systematic review and meta-analysis, Pereira et al (28) show, that vitamin D insufficiency increased COVID-19 mortality (OR = 1.82, 95% CI = 1.06–2.58).

Using UK Biobank data of 502,624 participants aged 37–73 years between 2006 and 2010, Hastie et al (29, 30) show that COVID-19 participants who had COVID-19 have lower vitamin-D level with median of 43.8 (IQR: 28.7–61.6) as compared with those who had no COVID-19 median of 47.2 (IQR: 32.7–62.7), Wilcoxon's p-value < 0.01. However, this result was not statistically significant after adjustment for confounders, though this did not make allowance for the fact that some of the confounders were also associated with Vitamin D deficiency.

In a cohort of 185 patients at the Medical University Hospital Heidelberg-Germany, vitamin-D deficiency was associated with higher risk of invasive mechanical ventilation and deaths after adjusting for age, gender, and comorbidities, HR of 6.12 (95% CI: 2.79–13.42, p < 0.001) and 14.73 (95% CI 4.16–52.19, p < 0.001) (31, 32).

Karahan and Katkat (33) show that vitamin-D insufficiency was present in 93.1% of the patients with severe-critical COVID-19, and that vitamin-D 25(OH) mean was significantly lower in patients with severe-critical COVID-19 compared with moderate COVID-19.

Despite all of these strong indications that Vitamin D could play an important role in the control of the COVID-19 pandemic, formally published papers have less than 500 patients recruited to randomized trials of Vitamin D(28). There has been one prospective observational study on 410 patients from India which at first sight was considered as a failure of Vitamin D supplementation (<https://www.researchsquare.com/article/rs-129238/v1>, currently undergoing major revision). As it gave Vitamin D to two thirds of those with Vitamin D deficiency who were also younger than those who weren't, the inverse of what is expected from other studies was seen. Overall there was a very low mortality rate and there was no difference in survival between those with and those without Vitamin D deficiency.

No data has been published from the UK about the effect of Vitamin D replacement. This is despite a continuous debate since April 2020 about Vitamin D deficiency contributing to excess deaths in the BAME community (<https://www.gov.uk/government/publications/covid-19-understanding-the-impact-on-bame-communities>). Throughout the year, the BAME community are known to have 20% less circulating vitamin D (34) and even in summer more than 30% have severe deficiency compared to less than 6% in white European population (35) and probably have done so for many of the years since birth.

In addition, there are two studies, one a randomized trial, that have clearly demonstrated that such individuals need 10 times more Vitamin D than recommended in the SACN report (36, 37).

Clearly, accelerating the role out of Vaccines around the world should not diminish. However as our data could not adjust for well established COVID-19 confounders such as Diabetes, Obesity, social deprivation and poverty, the increasing availability of simple finger-prick techniques (www.vitamindtest.org.uk) that speed up measuring of Vitamin D should make better selection for such therapy trials easier to recruit. Given reports published on line but still under review (see <https://www.imperial.ac.uk/media/imperial-college/institute-of-global-health-innovation/REACT-2-round-5-preprint.pdf> table 4) that the over 70's population have a 62% failure rate to produce IgG antibodies >21 days after first vaccination compared to 24% in 50-69 year olds and 7% in <50 year olds and the older age groups have a well recognized risk of lower Vitamin D levels, there could be a strong case to evaluate Vitamin D supplements in such patients.

The need to investigate Vitamin D deficiency as a cause of poor response to vaccine is further supported by 2 reports in patients known to have a high degree of Vitamin D deficiency. These are both currently under review and report diminished antibody response to COVID-19 vaccination. The first was in obese subjects (<https://www.medrxiv.org/content/10.1101/2021.02.24.21251664v1>) and the second was in patients with cancer (<https://www.kcl.ac.uk/news/delaying-second-vaccine-dose-cancer-patients-vulnerable-virus>)

Conclusion

The data from this statistical analysis shows a strong and statistically significant association between the Vitamin D deficiency and the total number of COVID-19 deaths in the 19 European countries included in this statistical analysis. The new vitamin D techniques for easier detection of deficiency using the finger prick technology should enable better selection of patients to benefit from treatment and prove it with appropriately selected COVID-19 patients in treatment trials and in trials aiming to reduce poor immune response in vaccine recipients.

Country	Total Deaths	Population	% Age 70+	Vitamin D	CMR
Portugal	9920	10196707	14.924	39.0	97.3
Spain	55441	46754783	13.799	42.5	118.6
Switzerland	9034	8654618	12.644	46.0	104.4
UK	96166	67886004	12.527	47.4	141.7
Belgium	20675	11589616	12.849	49.3	178.4
Italy	84674	60461828	16.24	50.0	140
Germany	51713	83783945	15.957	50.1	61.7
Austria	7330	9006400	13.748	56.0	81.4
Ireland	2870	4937796	8.678	56.4	58.1
Greece	5598	10423056	14.524	57.95	53.7
Netherlands	13528	17134873	11.881	59.5	79.0
France	72788	65273512	13.079	60.0	111.5
Hungary	11811	9660350	11.976	60.6	122.3
Czechia	15130	10708982	11.58	62.5	141.3
Denmark	1942	5792203	12.325	65.0	33.5
Norway	544	5421242	10.813	65.0	10.0
Finland	644	5540718	13.264	67.7	11.6
Sweden	11005	10099270	13.433	73.5	109.0
Slovakia	3894	5459643	9.167	81.5	71.3

Table 2: Spearman correlation (95% CI) between vitamin-D and the new number of COVID-19 deaths at different time-points

Time-Point	Date	Spearman ρ (95% CI)
1	21/03/2020 – 03/04/2020	-0.571 (-0.585, -0.553)
2	04/04/2020 – 17/04/2020	-0.614 (-0.629, -0.595)
3	18/04/2020 – 01/05/2020	-0.543 (-0.559, -0.525)
4	02/05/2020 – 15/05/2020	-0.478 (-0.496, -0.457)
5	16/05/2020 – 29/05/2020	-0.457 (-0.476, -0.436)
6	30/05/2020 – 12/06/2020	-0.285 (-0.309, -0.261)
7	13/06/2020 – 26/06/2020	-0.341 (-0.360, -0.320)
8	27/06/2020 – 10/07/2020	-0.431 (-0.448, -0.412)
9	11/07/2020 – 24/07/2020	-0.421 (-0.437, -0.403)
10	25/07/2020 – 07/08/2020	-0.365 (-0.378, -0.349)
11	08/08/2020 – 21/08/2020	-0.464 (-0.477, -0.449)
12	22/08/2020 – 04/09/2020	-0.443 (-0.455, -0.428)
13	05/09/2020 – 18/09/2020	-0.465 (-0.480, -0.447)
14	19/09/2020 – 02/10/2020	-0.395 (-0.413, -0.375)
15	03/10/2020 – 16/10/2020	-0.461 (-0.480, -0.439)
16	17/10/2020 – 30/10/2020	-0.457 (-0.475, -0.437)
17	31/10/2020 – 13/11/2020	-0.489 (-0.505, -0.471)
18	14/11/2020 – 27/11/2020	-0.508 (-0.523, -0.490)
19	28/11/2020 – 11/12/2020	-0.457 (-0.471, -0.440)
20	13/12/2020 – 25/11/2020	-0.447 (-0.462, -0.429)
21	26/12/2020 – 08/01/2021	-0.385 (-0.401, -0.366)
22	09/01/2021 – 22/01/2021	-0.405 (-0.421, -0.387)


Table3: Univariate and bivariate quasi-Poisson regression models. The percentage of age 70+ and binarized vitamin D variables were added together

Variable	Univariate		Bivariate	
	RR (95% CI)	z-value (P)	RR (95% CI)	z-value (P)
age 70+	0.978 (0.892, 1.073)	-0.471 (0.637)	0.964 (0.896, 1.036)	-1.001 (0.317)
vitamin D \geq 50	Reference			
vitamin D < 50	1.642 (1.274, 2.118)	3.823 (0.02)	1.663 (1.293, 2.140)	3.957 (<0.001)

Table 4: Poisson mixed effect regression models. Univariate models, where fitted with single fixed effect variable. The percentage of age 70+ and binarized vitamin D variables were added together as fix-effect predictors.

Variable	Univariate		Bivariate	
	RR (95% CI)	z-value (P)	RR (95% CI)	z-value (P)
age 70+	1.084 (0.921, 1.276)	0.972 (0.331)	1.013 (0.867, 1.183)	0.165 (0.869)
vitamin D \geq 50	Reference			
vitamin D < 50	2.197 (1.131, 4.271)	2.322 (0.020)	2.155 (1.068, 4.347)	2.145 (0.032)

Figure 1: Distribution of the total number of COVID-19 deaths with the vitamin-D group



REFERENCES

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
2. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. *Lancet Digit Health*. 2020;2(4):e201-e8.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199-207.
4. Massinga Loembe M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong JN. COVID-19 in Africa: the spread and response. *Nat Med*. 2020;26(7):999-1003.
5. Dyer O. Covid-19: Excess deaths point to hidden toll in South Africa as cases surge. *BMJ*. 2020;370:m3038.
6. Strang P, Furst P, Schultz T. Excess deaths from COVID-19 correlate with age and socio-economic status. A database study in the Stockholm region. *Ups J Med Sci*. 2020;125(4):297-304.
7. Mele M, Magazzino C. Pollution, economic growth, and COVID-19 deaths in India: a machine learning evidence. *Environ Sci Pollut Res Int*. 2020.
8. Adams-Prassl A, Cloyne J, Costa Dias M, Parey M, Ziliak JP. The COVID-19 Economic Crisis. *Fisc Stud*. 2020;41(3):489-92.
9. Gruber-Bzura BM. Vitamin D and Influenza-Prevention or Therapy? *Int J Mol Sci*. 2018;19(8).
10. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583.
11. Jolliffe DA, Camargo CA, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials. *medRxiv*. 2020.
12. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. *Clin Endocrinol (Oxf)*. 2020.
13. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. *JAMA Netw Open*. 2020;3(9):e2019722.
14. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS One*. 2020;15(9):e0239252.
15. Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS J*. 2020.
16. Maghbooli Z, Sahraian MA, Ebrahimi M, Pazoki M, Kafan S, Tabriz HM, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. *PLoS One*. 2020;15(9):e0239799.
17. Nikniaz L, Akbarzadeh M, A.,, Hosseinfard H, Hosseini M. Vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis www.medrxiv.org/content/10.1101/2021.01.04.21249219v1.full.pdf. *medrxiv* [Internet]. 2021.

18. Nogués X, Ovejero D, Quesada-Gomez JM, Bouillon R, al E. Calcifediol Treatment and COVID-19-Related Outcomes. . SSRN [Internet]. 2021. <http://dx.doi.org/10.2139/ssrn.3771318>
19. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res*. 2020;32(7):1195-8.
20. Hasell J, Mathieu E, Beltekian D, Macdonald B, Giattino C, Ortiz-Ospina E, et al. A cross-country database of COVID-19 testing. *Sci Data*. 2020;7(1):345.
21. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. *Aging Clin Exp Res*. 2020;32(8):1609-12.
22. Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch B, Bianchi ML, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *Eur J Endocrinol*. 2019;180(4):P23-P54.
23. Vickers AJ, Altman DG. Statistics notes: missing outcomes in randomised trials. *BMJ*. 2013;346:f3438.
24. Wang R, Peng J. Jackknife Empirical likelihood intervals for Spearman's rho. Peng, L. . *North American Actuarial Journal*. 2011;15(4):475–86.
25. Bates D, Mächler M, Bolker B, S W. "Fitting Linear Mixed-Effects Models Using lme4." *Journal of Statistical Software*. 2015;67(1):1-48.
26. . RCT. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.2020.
27. Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutr Bull*. 2014;39(4):322-50.
28. Pereira M, Dantas Damascena A, Galvao Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. *Crit Rev Food Sci Nutr*. 2020:1-9.
29. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr*. 2020;14(4):561-5.
30. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Corrigendum to "Vitamin D concentrations and COVID-19 infection in UK Biobank" [*Diabetes Metabol Syndr: Clin Res Rev* 2020 14 (4) 561-5]. *Diabetes Metab Syndr*. 2020;14(5):1315-6.
31. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D Deficiency and Outcome of COVID-19 Patients. *Nutrients*. 2020;12(9).
32. Radujkovic A, Merle U. Reply to: "Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: Vitamin D Deficiency and Outcome of COVID-19 Patients. *Nutrients* 2020, 12, 2757". *Nutrients*. 2020;12(12).
33. Karahan S, Katkat F. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey. *J Nutr Health Aging*. 2021;25(2):189-96.
34. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ, et al. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. *J Public Health (Oxf)*. 2020;42(3):451-60.
35. Sutherland JP, Zhou A, Leach MJ, Hypponen E. Differences and determinants of vitamin D deficiency among UK biobank participants: A cross-ethnic and socioeconomic study. *Clin Nutr*. 2020.
36. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. *J Bone Miner Res*. 2011;26(10):2341-57.

37. Kiely M, Cashman KD. Summary Outcomes of the ODIN Project on Food Fortification for Vitamin D Deficiency Prevention. *Int J Environ Res Public Health*. 2018;15(11).